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Abstract
Objective—An epidemic of prescription drug abuse is disproportionately impacting the mentally 
ill. We examined the utility of a state prescription drug monitoring database for assessing recent 
controlled substance prescribing to patients presenting for dual diagnosis treatment.
Method—In a community mental health center that provides integrated dual diagnosis care, we 
queried the Indiana Scheduled Prescription Electronic Collection and Tracking (INSPECT) system 
for all cases that were open as of August 2, 2011, and had been practitioner-diagnosed (per DSM-
IV criteria) by January 2, 2012. INSPECT provided a record of controlled substance dispensations 
to each patient; diagnostic evaluation was conducted blind from prescription data compilation 
covering the prior 12 months. Demographic data, insurance status, and DSM-IV diagnoses were 
compiled from the clinic's electronic medical record.
Results—The sample (N = 201) was 51% female, 56% white, and two-thirds uninsured. Over 
80% were dually diagnosed with substance use disorders and psychotic, mood, or anxiety 
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disorders. Nicotine and alcohol disorders were identified in most, with about a third diagnosed 
with cannabis, cocaine, or opioid disorders. A majority of patients (n = 115) had been prescribed 
opioids in the prior year, with nearly 1 in 5 prescribed an opioid and benzodiazepine 
simultaneously. Patients were dispensed a mean of 4 opioid prescriptions and 213 opioid pills. 
More opioid prescriptions correlated with opioid dependence (OR = 1.08; 95% CI, 1.016–1.145), 
and more prescribers correlated with personality disorder diagnoses (OR = 1.112; 95% CI, 1.001–
1.235). Higher rates and riskier patterns of controlled substance prescribing were identified in 
patients with Medicaid/Medicare insurance compared to uninsured patients.
Conclusions—Prescription drug monitoring is a powerful tool for assessing addictions and high 
frequencies of patient exposures to prescribed opioids in a dual diagnosis clinic. Improved 
prevention and treatment strategies for addictions as facilitated by more research and clinical use 
of prescription drug monitoring in psychiatric care are warranted.
Prescribing of controlled substances, particularly opioids, has grown dramatically over the 
past 2 decades in the United States, along with prescription drug addictions and lethal 
overdoses.1–3 One type of opioid, hydrocodone, is now the most commonly prescribed drug 
in the United States,4 and Americans are now more likely to die from a prescription drug 
overdose than from a car accident or suicide.1,2,5 Since 2000, 5-fold increases in lethal 
overdoses involving opioids have paralleled increases in their legal prescriptions by primary 
care doctors, emergency room physicians, dentists, and other specialists.1,5,6 As prescription 
drug deaths have surpassed those from illicit drugs,5 health and justice officials have 
become increasingly motivated to better educate the public and health professionals about 
the dangers of opioid medications and to develop new tools that can reduce adverse 
prescribing practices.3,7,8
State-supported prescription drug monitoring programs (PDMPs) allow practitioners to 
rapidly visualize records of controlled substance dispensations to their patients, enhancing 
identification of prescription drug abuse patterns.9,10 PDMPs may be particularly useful in 
behavioral health treatment settings: addictions, including those involving prescription 
drugs, are highly concentrated in populations with mental illness.11–19 Given “adverse 
selection,” where patients most vulnerable to addiction are the ones most likely to be 
prescribed opioids in large quantities,13,20 and biological vulnerability to addiction in mental 
illness,21,22 the regular use of PDMPs by psychiatric physicians could enhance the detection, 
interdiction, and treatment of prescription drug addictions. To our knowledge, there are no 
published studies demonstrating the use of PDMPs as either clinical or research tools in 
psychiatry, although a 2012 Ohio survey suggests few psychiatrists use them routinely.23 
The present study addresses this evidence gap while gauging the scope and penetrance of 
controlled substance prescribing in a community mental health outpatient population, with 
exploration of how controlled prescription patterns might correlate with specific diagnoses 
or differences in health insurance coverage.
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METHOD
Setting, Study Population, and Data Sources
The study population comprised patients in an adult outpatient dual diagnosis clinic of 
Midtown Mental Health Center in Indianapolis, affiliated with Indiana University School of 
Medicine. The clinic receives community referrals for patients with addictions and co-
occurring mental illnesses. It is staffed with psychiatrists, nurses, and master’s-level 
therapists (licensed clinical social workers, marriage and family therapists, mental health 
and addiction counselors) and bachelor’s-level case coordinators. Outpatient detoxification 
and long-term integrated dual diagnosis care combining pharmacotherapies with group and 
individual psychotherapies are provided. Treatment is open-ended and individualized 
according to clinical need, lasting weeks to years. All 292 patients active in the clinic on 
August 2, 2011, were candidates for the study. For final inclusion, patients needed an initial 
evaluation by a prescribing practitioner in the clinic by January 2, 2012. Practitioners 
included 2 addiction psychiatrists, 5 third-year psychiatry residents, and 2 advanced nurse 
practitioners. The study was approved under an Indiana University Institutional Review 
Board exempt waiver.
Two investigators (D.T.H., R.A.C.) compiled data from the clinic’s electronic medical 
record and the PDMP database. Indiana’s PDMP (Indiana Scheduled Prescription Electronic 
Collection and Tracking [INSPECT]) is housed in the Indiana Professional Licensing 
Agency and administered by the Indiana Board of Pharmacy. The database is accessible to 
registered practitioners and sworn law enforcement officials and compiles information on 
controlled substances dispensed, including the patient’s identifying information, prescription 
and fill dates, type, quantity, dosing schedule, pharmacy name and address, prescriber name 
and address, and payer. By law, all outpatient pharmacies must submit data to INSPECT 
within 7 business days of dispensing a controlled substance. At the time of the study, 
methadone programs (for opioid dependence) and inpatient pharmacies were exempt from 
reporting, and Indiana physicians were not required to use the database. INSPECT did not 
track noncontrolled substances, pseudoephedrine, and substances dispensed for less than a 
72-hour supply or Veterans Administration prescribing, as Veterans Administration systems 
were federally exempt from reporting until 2014.
Procedures
Electronic medical record review provided gender, age, ethnicity, insurance status (Table 1), 
date of initial prescriber evaluation, and DSM-IV diagnoses (text descriptions) made by the 
prescriber at initial evaluation. The large variety of Axis I non-substance use disorder (non-
SUD) diagnoses were compiled into 7 diagnostic classes (Table 2): (1) “psychotic spectrum” 
included schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic 
disorder, psychotic disorder not otherwise specified (NOS), and delusional disorder; (2) 
“bipolar spectrum” included bipolar I and II disorders and cyclothymia; (3) “unipolar 
spectrum” included major depressive disorder, dysthymia, and adjustment disorder with 
depressed mood; (4) “mood disorder NOS” indicated diagnostic uncertainty between bipolar 
versus unipolar spectrum disorder and included substance-induced mood disorders; (5) 
“anxiety spectrum” included specific phobias, generalized anxiety disorder, social phobia, 
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panic disorder, substance-induced anxiety disorder, adjustment disorder with anxiety, and 
anxiety disorder NOS; and (6) posttraumatic stress disorder (PTSD) and (7) obsessive-
compulsive disorder were counted as diagnostic classes separate from the other anxiety 
diagnoses. Other diagnoses (attention-deficit/hyperactivity disorder, eating disorders, 
traumatic brain injury, cognitive disorders) were sparse and not included in the analysis. 
Patients were coded as having (or not having) each of the 7 Axis I non-SUD categories. 
Fifteen drug-specific SUDs were coded as either present or absent (Table 2). For Axis II 
disorders, patients were coded as having a personality disorder if they were diagnosed with 
“traits” or had “provisional” or full diagnoses.
INSPECT provided a record of controlled substance dispensations to each patient over the 
12 months prior to the initial practitioner evaluation date, summarizing dispensations made 
before active treatment in the clinic. At the time of the study, INSPECT data were not being 
viewed to inform the initial assessment (diagnoses and INSPECT data were independent). 
The following INSPECT data were manually compiled: numbers of opioid prescriptions, 
opioid pills, benzodiazepine prescriptions, benzodiazepine pills, different prescribing 
physicians, and different pharmacies where prescriptions were filled. In rare instances 
involving liquid dispensations, liquid doses were converted into equivalent numbers of pills. 
To measure prescription patterns suggestive of diversion or drug abuse based on prior 
research,24 we calculated the number of incidents of overlapping prescriptions. An 
overlapping incident occurred when 2 consecutive dispensations (fills/refills) for the same 
drug class (eg, opioids) were made so that the second dispensation was filled early. 
Dispensation was considered “early” when the number of days of overlap was more than 
10% of the duration (in days) of the first prescription, or 3 days for prescriptions lasting 30 
days or less. If multiple prescriptions overlapped, we counted each overlap separately, 
making it possible to have more overlaps than individual prescriptions. Overlapping 
incidents for benzodiazepine and opioid prescriptions were considered within each class this 
way. For patients prescribed both benzodiazepines and opioids, instances of benzodiazepine-
opioid overlaps were counted when there was any time of overlap between dispensations.
Data Analyses
Multiple logistic regression using stepwise selection assessed how INSPECT data correlated 
with clinical diagnoses. As an exploratory analysis, the automated regression method 
alternated between forward selection and backward elimination. The procedure determined 
the contribution of each independent variable at each step. Five independent variables were 
analyzed together for each of the 6 outcome variables.25 After the procedure determined the 
significant independent variables, we added age, race, and gender to control for these factors 
in the final analysis. An initial set of 8 independent variables from INSPECT, numbers of 
(1) prescribers, (2) pharmacies, (3) opioid prescriptions, (4) overlapping opioid incidents, (5) 
opioid pills, (6) benzodiazepine prescriptions, (7) overlapping benzodiazepine incidents, and 
(8) benzodiazepine pills, was reduced in scope to 5 after preliminary Spearman correlations 
determined which variables were highly correlated: number of opioid pills and number of 
opioid prescriptions were highly correlated (Spearman r = 0.987; P <.0001), so we used 
only number of opioid prescriptions. Similarly, number of benzodiazepine pills and number 
of benzodiazepine prescriptions were highly correlated (Spearman r = 0.995; P <.0001), and 
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number of pharmacies and number of prescribers were highly correlated (Spearman r = 
0.944; P <.0001). So, we selected number of benzodiazepine prescriptions and number of 
prescribers for the modeling. Six outcome variables were assessed with determination of 
odds ratio (OR) estimates and 95% Wald confidence intervals (CIs): the presence of non-
SUD Axis I diagnosis (mental illness), dual diagnosis (the co-occurrence of a mental illness 
and SUD in the same patient), personality disorder, opioid use disorder (abuse and 
dependence), alcohol use disorder (abuse and dependence), and cocaine use disorder (abuse 
and dependence). To assess the impact of insurance status on prescribing, we dichotomized 
the population into those with no insurance (self-pay or hospital subsidy) versus 
government-supported insurance (Medicare and/or Medicaid) and applied nonparametric 
(Mann-Whitney U) testing to examine how these groups differed in terms of the 8 INSPECT 
variables. All analyses used P < .05 significance thresholds.
RESULTS
Demographics
As shown in Table 1, the final study sample (N = 201) was fairly evenly distributed by 
gender and the 2 major racial groups. Age was normally distributed, ranging from 18 to 64 
years, with a mean of 39.8 (SD = 10.6) years. Two-thirds of patients (66.2%) were 
uninsured, being self-pay and/or covered by the local hospital subsidy (ie, “written off”), 
with a smaller proportion (31.8%) covered by government (Medicaid/Medicare) insurance.
Clinical Diagnoses
Clinical diagnoses were made by the attending psychiatrist in 94 (47%) of the cases, by 
residents in 37 (18%) of the cases, and by nurse practitioners in 70 (35%) of the cases. 
Frequencies of clinical diagnoses are shown in Table 2. Large majorities of the population 
had an Axis I non-SUD (87.6%), an SUD (92.5%), and both (dual diagnosis) (80.1%). The 
number of diagnoses was fairly normally distributed, ranging from 1 to 10, with a mean of 
4.1 diagnoses per patient. A mood syndrome was suffered by 151 patients (75.1%), with 
anxiety disorders and PTSD present in 56 patients (27.9%). Lower rates of psychotic 
spectrum and personality disorders were diagnosed (10.0% for each).
Nicotine dependence and alcohol use disorders were the most common SUDs, each 
diagnosed in > 50% of the population and occurring together in n = 84 (41.8%) of the 
population. Cannabis, cocaine, and opioid dependence disorders were each diagnosed at 
comparable rates in approximately a third of cases.
Prescription Drug Monitoring Data
Controlled dispensations occurring in the 12 months before the initial diagnostic interview 
are described in Table 3. A majority of the sample (n = 115; 57%) had been prescribed an 
opioid. Hydrocodone was prescribed for 100 patients, oxycodone for 38, codeine for 11, 
morphine for 2, methadone for 2, buprenorphine for 13, and other opioids for 13. Nearly half 
of these opioid-medicated patients (n = 53) were also prescribed a benzodiazepine within the 
same year. Of these 53, the majority (n = 36; 17.9% of the total study population) had been 
prescribed opioids and benzodiazepines simultaneously. The mean number of opioid pills 
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dispensed per patient calculated over the entire study population (N = 201) was 213, nearly 
double the number of benzodiazepine pills. Among the 115 patients who had been 
prescribed an opioid, a mean of 372 opioid pills had been dispensed. All of these variables 
were skewed to the right, with fewer patients representing greater extremes of controlled 
prescription exposure (eg, 1 patient received 5,760 opioid pills in a year). Of the total of 
1,375 controlled prescriptions captured by INSPECT over the study population, 58.6% were 
for opioids, 34.6% were for benzodiazepines, and 6% were for other controlled substances 
(pregabalin, various barbiturates, amphetamines, and modafinil).
According to the logistic regression, number of opioid prescriptions significantly increased 
the odds of being diagnosed with opioid dependence (OR = 1.08; 95% CI, 1.016–1.145), 
with each unit increase in number of opioid prescriptions producing an 8% increase in the 
likelihood of an opioid dependence diagnosis. However, prescribed opioids significantly 
decreased the odds of being diagnosed with an alcohol use disorder (OR = 0.905; 95% CI, 
0.859–0.955), having a non-SUD Axis I disorder (OR = 0.945; 95% CI, 0.900–0.992), and 
having a dual diagnosis (OR = 0.938; 95% CI, 0.896–0.982). Each unit increase in opioid 
prescriptions reduced the odds of being diagnosed with an alcohol disorder by 9.1%, a non-
SUD Axis I disorder by 5.5%, and dual diagnosis by 6.2%. The number of opioid 
prescriptions, overlapping opioid prescription incidents, benzodiazepine prescriptions, or 
benzodiazepine overlaps was not otherwise predictive of any of the other outcome variables. 
An increase in the number of prescribers was predictive of a personality disorder (OR = 
1.112; 95% CI, 1.001–1.235), so that each unit increase in number of prescribers increased 
the odds of being diagnosed with a personality disorder by 11.2%.
Patients with government-supported health insurance (n = 64) versus those with no 
insurance (n = 133) had significantly higher rates of prescribing patterns indicative of 
prescription drug risk across all 8 of the outcomes we measured with respect to opioids, 
benzodiazepines, and their combinations (Table 4).
DISCUSSION
This study demonstrates PDMP utility in quantifying controlled substance prescribing in a 
treatment-seeking mentally ill/addicted population. Our results show that exposure to legally 
prescribed opioids is substantial and typical in this population, consistent with prior 
descriptions of “adverse selection,” where patients most vulnerable to addictive or other 
dangerous effects of opioids are actually more likely to be prescribed opioids.20 On average, 
any given patient in the sample had been prescribed controlled substances by 2.6 different 
prescribers and 213 opioid pills via 4 different prescriptions. These numbers are 
substantially greater than the average number of opioid pills dispensed to American adults in 
2007 (about 120).5 Nearly 1 in 5 patients had been prescribed an opioid in combination with 
a benzodiazepine, which, outside of comfort care for terminally ill patients, intensive care 
units, or detoxification settings, is a controversial and potentially dangerous combination 
with little evidence-based justification.26–28
The clinical population we sampled had a large majority of dual diagnosis patients, 
consistent with many studies showing that mental illness and addiction comorbidity is 
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typical in psychiatric populations.29,30 In our sample, psychotic, mood, and anxiety 
diagnoses occurred 3 to 10 times more frequently than in the general population.31 Alcohol 
and nicotine use disorders were diagnosed at 2- to 3-fold higher rates, while cannabis, 
opioid, and cocaine use disorders were diagnosed 5 to 10 times more frequently than in the 
general population.32–34 The relative proportions of mental illnesses, addictions, and their 
comorbidities found in our sample were also similar to those in large population studies (eg, 
National Comorbidity Survey).31,34 For instance, psychotic disorders were diagnosed less 
frequently than mood or anxiety disorders, while nicotine dependence was identified 
frequently in patients with alcohol disorders.34 In sum, with respect to Axis I disorders, the 
clinical population we sampled is likely generalizable to many moderately to severely ill 
psychiatric populations. Notably, however, we suspect that this study identified an 
inaccurately low rate of personality diagnoses, which is common in studies that do not 
employ structured interviewing.35
Unsurprisingly, we found that the number of opioid prescriptions was associated with the 
likelihood of an opioid dependence diagnosis. Moreover, the number of controlled substance 
prescribers correlated with risk of a personality disorder diagnosis. This also is not 
surprising considering that pathologic social dynamics and affective symptomatology in 
these disorders can produce overutilization of health care resources, polypharmacy, and 
unstable doctor-patient relationships.36,37 More unexpectedly, the number of opioid 
prescriptions was associated with a lower likelihood of being diagnosed with alcohol 
dependence, a non-SUD disorder, or dual diagnosis. These findings, observed in a clinical 
sample that contains large majorities of patients with each of these diagnostic conditions, 
could be due to a number of complex dynamics that warrant further investigation. In this 
population, addiction to 1 drug class (eg, opioids) may financially and motivationally crowd 
out addiction to another drug (alcohol). Additionally, comorbid alcohol or dual diagnosis 
disorders with opioid use disorders may be particularly lethal (and thus occur in lower 
frequencies) or lead to greater advancement to nonprescribed opioids (eg, heroin). 
Alternatively, these findings may reflect less access to physicians who prescribe opioids 
among the most severely mentally ill and addicted people.
Having Medicaid or Medicare insurance, compared to having no insurance, was 
significantly associated with greater opioid and benzodiazepine exposure with respect to 
every INSPECT variable we analyzed. This finding is consistent with prior research 
suggesting that health care reimbursed by these programs is associated with relatively 
prolific prescribing of controlled substances.19,38,39 Inciardi and colleagues39,40 have 
documented criminal networks that specifically target, accumulate, and sell prescription 
drugs acquired from Medicaid and Medicare patients. Notably, in our study, both insured 
and uninsured groups were poor people suffering from high rates of dual diagnosis. For 
either group, we were not able to determine how many or which pills we detected by PDMP 
had been diverted (given away, lost, stolen, sold) or consumed. At the time of this study, 
government insurance programs in Indiana readily reimbursed prolific prescribing of opioids 
for pain indications without requiring findings on clinical examination, screening for mental 
illness or addictions, urine drug testing, or other significant regulatory oversight. 
Meanwhile, these insurance plans maintained arduous administrative barriers and provided 
inadequate or no funding for many evidence-based addiction treatments.41,42 Accordingly, 
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these findings may point to a critical unmet need to achieve greater parity of insurance 
reimbursement for addictions and dual diagnosis treatment and for routine PDMP usage in 
the prevention and treatment of prescription drug addictions.
Our study design has several limitations. First, we did not systematically assess whether 
prescribing detected with INSPECT was beneficial versus harmful. Discovery and tracking 
of clinical indications and competence and types of prescribing physicians and/or centers 
would have been prohibitively difficult. However, only 13% of 115 patients prescribed 
opioids were treated with methadone or buprenorphine, with methadone being prescribed for 
pain in 100% of cases, indicating that the vast majority of opioids were for pain indications. 
Notably, in our clinical experience after this data collection, we found that controlled 
substance prescribing to our patients detected on INSPECT was often detrimental, requiring 
direct interdiction via doctor-to-doctor communications. A second major limitation was the 
lack of standardized scales for making diagnoses. We relied on a range of clinician types 
and did not incorporate diagnostic evolution after initial assessment. Larger studies using 
standardized diagnostic measures and inclusion of psychiatrically healthy controls in more 
diverse clinical settings are needed. Nevertheless, the approach we used was naturalistic 
with regard to how diagnoses are made in nonresearch settings, and it allowed us to avoid 
selection biases introduced by obtaining informed consent. Finally, this study did not 
observe how PDMP data would have influenced diagnoses or treatment planning involving 
professional communications or psychotherapeutic, educational, and psychopharmacologic 
modalities of care. Future studies examining these effects and examining PDMPs as 
outcome measures in psychiatric care are warranted.
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Clinical Points
■ Prescription drug monitoring programs (PDMPs) should be utilized routinely 
as assessment tools in behavioral health, especially in addictions and dual 
diagnosis care.
■ Patterns of controlled substance prescribing detected by PDMPs may predict 
and/or support specific clinical diagnoses such as opioid dependence and 
personality disorders.
■ Prescribing of single types or combinations of potentially dangerous and 
psychiatrically deleterious controlled substances by non–behavioral health 
professionals may be a significant and pervasive problem in mentally ill and 
addicted populations.
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Table 1
Demographic Characteristics of Patients Included in the Study (N = 201)
Characteristic n (%)
Age
  ≤ 25 y 22 (10.9)
  26–45 y 117 (58.2)
  > 45 y 62 (30.8)
Gender
  Male 99 (49.3)
  Female 102 (50.7)
Race
  White 112 (55.7)
  Black 86 (42.9)
  Other 3 (1.5)
Insurance
  Uninsured 12 (6.0)
  Hospital subsidy 121 (60.2)
  Medicaid 45 (22.4)
  Medicare 19 (9.5)
  Private/other 4 (2.0)
J Clin Psychiatry. Author manuscript; available in PMC 2015 April 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hackman et al. Page 13
Table 2
Clinical Diagnoses Among Patients (N = 201)
Diagnosis n (%)
Axis I non-substance use disorder
Any Axis I non-substance use disorder 176 (87.6)
No Axis I non-substance use disorder 25 (12.4)
Psychotic spectrum 20 (10.0)
Bipolar spectrum 28 (13.9)
Unipolar spectrum 92 (45.8)
Mood NOS 31 (15.4)
Anxiety spectruma 32 (16.0)
PTSD 24 (11.9)
OCD 3 (1.5)
Axis II (personality disorder)b
Any 20 (10.0)
None 181 (90.0)
Axis I substance use disorder
Any Axis I substance use disorder 186 (92.5)
No Axis I substance use disorder 15 (7.5)
Alcohol abuse 16 (8.0)
Alcohol dependence 115 (57.2)
Nicotine dependence 115 (57.2)
Cannabinoid abuse 19 (9.5)
Cannabinoid dependence 75 (37.3)
Cocaine abuse 7 (3.5)
Cocaine dependence 74 (36.8)
Opioid abuse 3 (1.5)
Opioid dependence 59 (29.4)
Sedative/hypnotic abuse 5 (2.5)
Sedative/hypnotic dependence 16 (8.0)
Amphetamine abuse or dependence 9 (4.5)
Hallucinogen abuse or dependencec 5 (2.5)
Inhalant dependence 1 (0.5)
Polysubstance dependence 39 (19.4)
Dual diagnosis comorbidity
Axis I non-SUD with SUD 161 (80.1)
Only Axis I non-SUD 15 (7.5)
Only Axis I SUD 25 (12.4)
a
Includes phobias, generalized anxiety disorder, social phobia, substance-induced anxiety disorder, anxiety disorder NOS; does not include PTSD 
or OCD.
bCoded present if the terms “traits” or “provisional” or the full diagnosis was mentioned: borderline personality disorder (n = 10), antisocial 
personality disorder (n = 6), obsessive-compulsive personality disorder (n = 1), personality disorder NOS (n = 3).
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cincludes ketamine, lysergic acid diethylamide (LSD), phencyclidine (PCP).
Abbreviations: NOS = not otherwise specified, OCD = obsessive-compulsive disorder, PTSD = posttraumatic stress disorder, SUD = substance use 
disorder.
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Table 3
INSPECT Report Variables Over the Study Sample (N = 201)
INSPECT Variable Mean SD Maximum
No. of prescribers 2.6 3.7 23
No. of pharmacies 2.0 2.8 16
Opioid prescriptions 4.0 7.3 42
Overlapping opioid incidents 1.3 6.8 85
Opioid pills 212.9 590.7 5,760
Benzodiazepine prescriptions 2.4 7.8 92
Overlapping benzodiazepine incidents 2.3 23.5 331
Benzodiazepine pills 112.5 332.4 2,636
Patients prescribed opioids and benzodiazepines within 1 year n %
    No opioid or benzodiazepine 76 38
    Benzodiazepine, but no opioid 10 5
    Opioid, but no benzodiazepine 62 31
    Both opioid and benzodiazepinea 53 26
a
Thirty-six patients (18%) were prescribed both opioids and benzodiazepines with overlapping prescription fills, and 17 (8.5%) were prescribed 
opioids and benzodiazepines at different times without overlapping regimens.
Abbreviation: INSPECT = Indiana Scheduled Prescription Electronic Collection and Tracking.
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